Revumenib (SNDX-5613)

Menin Inhibitor
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
AUGMENT-101-2A*
(monotherapy)
R/R KMT2Ar ALL
AUGMENT-101-2B*
(monotherapy)
R/R KMT2Ar AML
AUGMENT-101-2C
(monotherapy)
R/R NPM1m AML
AUGMENT-102
(chemotherapy combination)
R/R KMT2Ar and
NPM1m acute leukemias
BEAT-AML
(venetoclax/azacitidine combo)
Frontline KMT2Ar and
NPM1m AML
INTERCEPT
(monotherapy)
MRD- progression in
KMT2Ar and NPM1m AML
Colorectal Cancer
(monotherapy)
Unresectable metastatic
microsatellite stable CRC

Axatilimab (SNDX-6352)

Anti-CSF-1R mAB
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
AGAVE-201*
(monotherapy)
Chronic GVHD

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
Entinostat
Under review

Revumenib (SNDX-5613)

Menin Inhibitor

AUGMENT-101-2A*

R/R KMT2Ar ALL

Registration

AUGMENT-101-2B*

R/R KMT2Ar AML

Registration

AUGMENT-101-2C

R/R NPM1m AML

Pivotal

AUGMENT-102

R/R KMT2Ar and NPM1m acute leukemias

Phase 1

BEAT-AML

Frontline KMT2Ar and NPM1m AML

Phase 1

INTERCEPT

MRD- progression in KMT2Ar and NPM1m AML

Phase 1

Colorectal Cancer

Unresectable metastatic microsatellite stable CRC

Phase 1

Axatilimab (SNDX-6352)

Anti-CSF-1R mAB

AGAVE-201*

Chronic GVHD

Registration

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor

Entinostat

Under Review

*Submission of registrational filing expected by year-end 2023